Matthew Coffey

3.0k total citations · 1 hit paper
45 papers, 2.1k citations indexed

About

Matthew Coffey is a scholar working on Genetics, Biotechnology and Infectious Diseases. According to data from OpenAlex, Matthew Coffey has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 27 papers in Biotechnology and 26 papers in Infectious Diseases. Recurrent topics in Matthew Coffey's work include Virus-based gene therapy research (39 papers), Viral gastroenteritis research and epidemiology (26 papers) and Cancer Research and Treatments (26 papers). Matthew Coffey is often cited by papers focused on Virus-based gene therapy research (39 papers), Viral gastroenteritis research and epidemiology (26 papers) and Cancer Research and Treatments (26 papers). Matthew Coffey collaborates with scholars based in United States, United Kingdom and Canada. Matthew Coffey's co-authors include Patrick W.K. Lee, James E. Strong, Peter Forsyth, Alan Melcher, Richard G. Vile, Sandra Nishikawa, Kensuke Hirasawa, Kara L. Norman, Kevin J. Harrington and Elizabeth J. Ilett and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Matthew Coffey

44 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reovirus Therapy of Tumors with Activated Ras Pathway

1998 626 citations Matthew Coffey, Patrick W.K. Lee et al. profile →

Peers

Countries citing papers authored by Matthew Coffey

Since Specialization

Citations

This map shows the geographic impact of Matthew Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Coffey more than expected).

Fields of papers citing papers by Matthew Coffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Coffey. The network helps show where Matthew Coffey may publish in the future.

Co-authorship network of co-authors of Matthew Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Coffey. A scholar is included among the top collaborators of Matthew Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Coffey. Matthew Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma. 2021 ·Journal of Clinical Oncology ·Devalingam Mahalingam, Siqi Chen, Ping Xie, Aparna Kalyan, Sheetal Kircher, Masha Kocherginsky, Jiahui Xu, (unknown), (unknown), Elena Vagia, Grey Wilkinson, Matthew Coffey, Mary F. Mulcahy, Al B. Benson, Bin Zhang	3
2	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS -Mutated Colorectal Cancer 2020 ·Molecular Cancer Therapeutics ·Sanjay Goel, Allyson J. Ocean, (unknown), Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, (unknown), (unknown), Matthew Coffey, Radhashree Maitra	25
3	41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1) 2020 ·Annals of Oncology ·Luís Manso, Patricia Villagrasa, Núria Chic, Juan Miguel Cejalvo, Yann Izarzugaza, Blanca Cantos, (unknown), Manel Juan, Blanca González‐Farré, R. Laeufle, Gerard J. Nuovo, Grey Wilkinson, Matthew Coffey, Ana González, Eduardo Martínez de Dueñas, Laia Paré, Fernando Salvador, Xavier González, Aleix Prat, Joaquín Gavilá Gregori	2
4	Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy 2018 ·Cancer Immunology Research ·(unknown), Lynette P. Steele, Aat A. Mulder, Diana J.M. van den Wollenberg, Timothy Kottke, Jill Thompson, Matthew Coffey, Rob C. Hoeben, Richard G. Vile, Alan Melcher, Elizabeth J. Ilett	53
5	A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma 2017 ·Cancer Chemotherapy and Pharmacology ·Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley, (unknown), Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Matthew Coffey, Brad Thompson, John Sarantopoulos	68
6	Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients 2017 ·Annals of Oncology ·Andres Gutierrez, Cyprian B. Reid, Michael Crawford, (unknown), (unknown), (unknown), Alan D. Penman, (unknown), (unknown), (unknown), Matthew Coffey	2
7	Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer 2017 ·Oncotarget ·Radhashree Maitra, Titto Augustine, (unknown), (unknown), Matthew Coffey, Sanjay Goel	19
8	The effects of oncolytic reovirus in canine lymphoma cell lines 2014 ·Veterinary and Comparative Oncology ·(unknown), (unknown), Masaya Igase, Matthew Coffey, Shunsuke Noguchi, Masaru Okuda, Takuya Mizuno	16
9	Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan 2014 ·Oncotarget ·Radhashree Maitra, Raviraja N. Seetharam, Lydia Tesfa, Titto Augustine, Lidija Klampfer, Matthew Coffey, John M. Mariadason, Sanjay Goel	40
10	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary, (unknown), Paul J. Christos, (unknown), Erika Florendo, (unknown), Joseph T. Ruggiero, E Popa, Melissa L. Wilson, Mohammad H. Ghalib, (unknown), Umang Shah, Lakshmi Rajdev, (unknown), George M. Gill, Matthew Coffey, Manish A. Shah, Sanjay Goel	9
11	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples 2012 ·Modern Pathology ·Gerard J. Nuovo, Michela Garofalo, Nicola Valeri, (unknown), Stefano Volinia, David E. Cohn, Mitch A. Phelps, Kevin J. Harrington, Richard G. Vile, Alan Melcher, Evanthia Galanis, (unknown), (unknown), Karen J. Scott, Ailsa Rose, Giles J. Toogood, Matthew Coffey	45
12	Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy 2012 ·Gene Therapy ·Victoria Roulstone, Katie Twigger, S. Zaidi, (unknown), Joan Kyula, Charles L. White, Martin McLaughlin, R. Seth, Eleni Karapanagiotou, David Mansfield, Matthew Coffey, Gerard J. Nuovo, Richard G. Vile, Hardev Pandha, Alan Melcher, Kevin J. Harrington	48
13	Reovirus-based therapy for cancer 2009 ·Expert Opinion on Biological Therapy ·Kevin R. Kelly, Steffan T. Nawrocki, Alain C. Mita, Matthew Coffey, Francis J. Giles, Monica Mita	54
14	Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells 2009 ·Molecular Cancer ·Shizuko Sei, (unknown), (unknown), Kunio Nagashima, Ralph E. Parchment, Matthew Coffey, Robert H. Shoemaker, Joseph E. Tomaszewski	93
15	Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity 2009 ·Gene Therapy ·Elizabeth J. Ilett, Robin Prestwich, Timothy Kottke, Fiona Errington‐Mais, Jill Thompson, Kevin J. Harrington, Hardev Pandha, Matthew Coffey, Peter J. Selby, Richard G. Vile, Alan Melcher	99
16	A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer 2009 ·Journal of Clinical Oncology ·Hendrik‐Tobias Arkenau, JEFF EVANS, (unknown), Patricia Roxburgh, (unknown), Matthew Coffey, George M. Gill, K.L. Mettinger, Bruce Thompson, Johann S. de Bono	2
17	Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma 2008 ·Gene Therapy ·Fiona Errington‐Mais, Charles L. White, Katie Twigger, Ailsa Rose, Karen J. Scott, Lynette P. Steele, Elizabeth J. Ilett, Robin Prestwich, (unknown), Matthew Coffey, Peter J. Selby, Richard G. Vile, Kevin J. Harrington, Alan Melcher	86
18	Hsp90 Phosphorylation Is Linked to Its Chaperoning Function 2001 ·Journal of Biological Chemistry ·Yaguang Zhao, (unknown), Gustavo Leone, Matthew Coffey, Bryce Weber, Patrick W.K. Lee	88
19	Active Participation of Hsp90 in the Biogenesis of the Trimeric Reovirus Cell Attachment Protein ς1 1998 ·Journal of Biological Chemistry ·(unknown), Matthew Coffey, Patrick W.K. Lee	19
20	C-terminal Trimerization, but Not N-terminal Trimerization, of the Reovirus Cell Attachment Protein Is a Posttranslational and Hsp70/ATP-dependent Process 1996 ·Journal of Biological Chemistry ·Gustavo Leone, Matthew Coffey, (unknown), Roy Duncan, (unknown), Patrick W.K. Lee	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact